Cerebral Palsy Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.40 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cerebral Palsy Treatment Market Analysis
The cerebral palsy treatment market is expected to register a significant CAGR of 4.4% during the study period.
- COVID-19 had a considerable effect on the cerebral palsy treatment market. The study published in the Journal of Rehabilitation Medicine in November 2020 stated that respiratory dysfunction was one of the leading causes of morbidity and mortality in individuals with cerebral palsy (CP). Individuals with pre-existing respiratory disorders were at greater risk for respiratory complications if they contracted COVID-19 due to the spasticity in the diaphragm, thereby increasing the risk of morbidity associated with cerebral palsy.
- Furthermore, according to the study published in the Indian Journal of Orthopediatrics in January 2022, the results showed that the caregivers among cerebral palsy children had been largely affected by the COVID-19 pandemic in terms of functional decline, deformity progression, inability to receive regular physical treatment or orthotics, and behavioral problems.
- The factors propelling the cerebral palsy treatment market growth are the growing burden of cerebral palsy, the rise in investments, technological advancements, government initiatives, and other key strategies adopted by the key market players. According to the article published by Congress.gov in March 2022, cerebral palsy is the most common motor disability in children, affecting more than 1,000,000 Americans, 1 in 345 children, and over 17,000,000 people worldwide.
- The growing research and development activities in the development of therapeutics for cerebral palsy are driving the market growth. For instance, as per clinicaltrials.gov, in January 2022, Neurocrine Biosciences initiated a phase 3 clinical trial, a randomized, double-blind, placebo-controlled study to evaluate the efficacy of valbenazine versus placebo in participants aged 6 to 70 years for the treatment of dyskinesia due to cerebral palsy (DCP). The study is expected to be completed by August 2024. Positive responses from such studies evaluating the efficacies of existing treatments for cerebral epilepsy will increase its adoption, thus boosting the studied market during the study period.
- Moreover, rising strategic initiatives such as mergers and partnerships by key market players will expand the offerings in the market, which will boost the studied market. For instance, in April 2022, the Japanese subsidiary of Control Bionics signed an exclusive distribution agreement with Double Research and Development Co., Ltd. To start full-scale operations to better solve the communication challenges of people with severe disabilities in Japan through technology. Control Bionics has been working with users living with severe disabilities, including cerebral palsy (CP) and others.
- Rising investments in the market will propel technological innovation and expand the geographical presence, which will drive the market. For instance, in April 2022, Jupiter Lifeline Hospitals is planning to set up a state-of-the-art neuro-rehabilitation center in the United Kingdom with an investment of around 50 million pounds. The proposed rehabilitation center in the country is expected to have a 100-bed inpatient capacity, which will benefit patients with stroke, traumatic brain injury, cerebral palsy, spinal cord injury, Parkinson's disease, progressive and non-progressive neurological disorders, and sports injuries.
- Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, the side effects of drugs associated with cerebral palsy are expected to hinder market growth during the study period.
Cerebral Palsy Treatment Market Trends
Spastic Cerebral Palsy Segment is Expected to Account for the Large Market Share Over the Forecast Period
- Spastic cerebral palsy is a developmental disorder caused by damage to the brain before birth, during delivery, or within the first few years of life. This condition prevents the normal development of motor function. Spastic cerebral palsy causes increased muscle tone, stiff muscles, and difficulty walking. Treatments for spastic cerebral palsy include physical therapy, medications, and surgery. The different types of spastic cerebral palsy are spastic diplegia, spastic Hemiplegia, and spastic Quadriplegia.
- Factors such as high incidences of spastic cerebral palsy, rising research and development activities, and increasing investments are expected to boost the studied market growth significantly.
- According to a March 2022 update of the article published by CerebralPalsyGuidance.com, spastic cerebral palsy is the most common form of cerebral palsy, accounting for 70% to 80% of all people diagnosed. Therefore, due to the high burden of the diseases, there is an increasing demand for its therapeutics, thus boosting the investments and research activities in the segment, thus contributing to the significant growth of the market.
- The growing research activities in the segment will fuel the market. For instance, as per Clinicaltrials.gov, in December 2022, a study update was given by Jazz Pharmaceuticals on the effects of Sativex treatment spastic cerebral palsy in a population of children and adolescents aged from 8 to 18 years, and it was found to be safe and effective. Positive results from such studies will increase the launch of new medication and thereby lead to its adoption, thus driving the market.
- Moreover, the study published in BMC Neurology in March 2022 demonstrated that intrathecal injection of umbilical cord blood mononuclear cells (UCB-MNC) was safe and effective in children with cerebral palsy. The safety and effectiveness of therapies for spastic cerebral palsy are anticipated to drive segment growth due to increased adoption.
- Thus, due to factors such as rising safety and effectiveness of treatments, the rising prevalence of disease, among others, is expected to contribute to the significant growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
- The primary driving factors for the growth of the North American cerebral palsy market are the rising burden of cerebral palsy, growing research and development activities, increasing investments, supporting government initiatives, and key initiatives taken by the key market players.
- The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, According to an article published by Congress.gov in March 2022, in the United States, more than 10,000 babies are diagnosed with cerebral palsy each year. The high prevalence of cerebral palsy in the country is increasing the demand for its therapeutics. Therefore, pharmaceutical companies are investing heavily in the therapeutic area, which will significantly drive the market.
- Rising investments in the studied market will bring innovation to the studied market, thereby boosting the accessibility of therapeutics for cerebral palsy, fueling the market. For instance, in March 2022, Adam Boehler, in partnership with Martin Ventures, invested in StationMD, a healthcare company that uses telemedicine to deliver medical care to people with intellectual and developmental disabilities (I/DD). That includes individuals with autism spectrum disorder, Down syndrome, and cerebral palsy. This will increase the accessibility of treatments to people with cerebral palsy, thereby driving the market.
- Additionally, in January 2022, Governor of New York Kathy Hochul invested in Cerebral Palsy Associations of New York State. This proposal includes USD 2 billion in workforce funding and USD 500 million in cost of living to support a sustainable care infrastructure and, therefore, focus on addressing the current workforce crisis. Such funding helps in better and easier access to treatments for cerebral palsy patients, driving the market growth.
- Moreover, strategic initiatives adopted by key market players creating awareness for cerebral palsy are expected to drive market growth. For instance, in February 2022, Edward R. Matthews, CEO of ADAPT Community Network, and Armando A. Contreras, President and CEO of United Cerebral Palsy, launched Start Here, a new digital platform that will provide caregivers with a trusted source for guidance on everything from the basics of cerebral palsy and other intellectual and developmental disabilities, as well as managed care advice about how to be an effective advocate for their child. This will create awareness for therapeutics for cerebral palsy, thus increasing its demand, which will lead to the lucrative growth of the market.
- Therefore, due to the rising incidence of diseases, rising funding for CP treatments, and rising initiatives from the key market players, the studied market is expected to lead to lucrative growth of the market in North America.
Cerebral Palsy Treatment Industry Overview
The cerebral palsy treatment market is moderately competitive with several market players. The factors owing to the competition include strategies such as mergers and acquisitions and partnerships adopted by key market players to expand their geographical reach and products offered to them. Some players operating in the market are AbbVie Inc., Ipsen Biopharmaceuticals Inc., Merz GmbH & Co. KGaA, Teva Pharmaceutical Industries Ltd., Supernus Pharmaceuticals Inc., and others.
Cerebral Palsy Treatment Market Leaders
Ipsen Biopharmaceuticals Inc.
Merz GmbH & Co. KGaA
Teva Pharmaceutical Industries Ltd.
Supernus Pharmaceuticals, Inc.
Abbvie Inc.
*Disclaimer: Major Players sorted in no particular order
Cerebral Palsy Treatment Market News
- July 2023: Cerebral Palsy Alliance (CPA) launched a new brand campaign with Cummins & Partners. The campaign 'A Life Changing Movement' highlights some of the ways CPA helps in exploring the potential of children and adults with cerebral palsy.
- May 2023: The Cerebral Palsy Foundation entered a partnership with University College Cork, Trinity College Dublin, and the Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences to launch a program of excellence to revolutionize cerebral palsy care in Ireland. As per the program, around 150 babies receive a cerebral palsy diagnosis in Ireland every year.
Cerebral Palsy Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Cerebral Palsy
4.2.2 Increasing Investments and Advancements by Market Players
4.3 Market Restraints
4.3.1 Side Effect Associated With The Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD)
5.1 By Disease Type
5.1.1 Spastic Cerebral Palsy
5.1.2 Dyskinetic Cerebral Palsy
5.1.3 Ataxic Cerebral Palsy
5.1.4 Mixed Cerebral Palsy
5.2 By Treatment Type
5.2.1 Surgery
5.2.2 Medication
5.2.2.1 Anticholinergics
5.2.2.2 Anticonvulsants
5.2.2.3 Antidepressants
5.2.2.4 Antispastic
5.2.2.5 Other Medication (Anti-inflammatories and Stool Softeners)
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Ipsen Biopharmaceuticals Inc.
6.1.3 Merz GmbH & Co. KGaA
6.1.4 Teva Pharmaceutical Industries Ltd
6.1.5 Supernus Pharmaceuticals Inc.
6.1.6 Proveca Ltd
6.1.7 Novartis AG
6.1.8 Revance Therapeutics
6.1.9 Baylx Inc.
6.1.10 Hope Biosciences
6.1.11 Lannett Co Inc
6.1.12 MGC Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Cerebral Palsy Treatment Industry Segmentation
Cerebral palsy refers to a group of symptoms that involve difficulty moving and muscle stiffness (spasticity). It results from brain malformations that occur before birth as the brain is developing or from brain damage that occurs before, during, or shortly after birth.
The cerebral palsy treatment market is segmented by disease type (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, mixed cerebral palsy), treatment type (surgery and medication), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above-mentioned segments.
| By Disease Type | |
| Spastic Cerebral Palsy | |
| Dyskinetic Cerebral Palsy | |
| Ataxic Cerebral Palsy | |
| Mixed Cerebral Palsy |
| By Treatment Type | |||||||
| Surgery | |||||||
|
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cerebral Palsy Treatment Market Research FAQs
What is the current Global Cerebral Palsy Treatment Market size?
The Global Cerebral Palsy Treatment Market is projected to register a CAGR of 4.40% during the forecast period (2024-2029)
Who are the key players in Global Cerebral Palsy Treatment Market?
Ipsen Biopharmaceuticals Inc., Merz GmbH & Co. KGaA, Teva Pharmaceutical Industries Ltd., Supernus Pharmaceuticals, Inc. and Abbvie Inc. are the major companies operating in the Global Cerebral Palsy Treatment Market.
Which is the fastest growing region in Global Cerebral Palsy Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Cerebral Palsy Treatment Market?
In 2024, the North America accounts for the largest market share in Global Cerebral Palsy Treatment Market.
What years does this Global Cerebral Palsy Treatment Market cover?
The report covers the Global Cerebral Palsy Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Cerebral Palsy Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Cerebral Palsy Treatment Industry Report
Statistics for the 2024 Cerebral Palsy Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cerebral Palsy Treatment analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
